Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis
NCT ID: NCT04206163
Last Updated: 2024-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
78 participants
INTERVENTIONAL
2020-01-20
2024-06-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis
NCT03347760
Diagnostic Criteria in Cardiac Sarcoidosis
NCT04737317
DEtection of Cellular Inflammation With FERumoxytol in the HEART
NCT02319278
MyoStrain CMR for the Detection of Cardiotoxicity
NCT03543228
Evaluation of MyoStrain™ in Clinical Practice
NCT03825224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute myocarditis
Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.
68Ga-DOTA-TOC PET/CT
Somatostatin receptor imaging
Blood sample
Analysis of inflammatory biomarkers
Cardiac sarcoidosis
Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.
68Ga-DOTA-TOC PET/CT
Somatostatin receptor imaging
Blood sample
Analysis of inflammatory biomarkers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68Ga-DOTA-TOC PET/CT
Somatostatin receptor imaging
Blood sample
Analysis of inflammatory biomarkers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Provision of written informed consent
* All patients between the age of 18 and 85 of both genders
* Newly clinically suspected acute myocarditis or newly clinically suspected cardiac sarcoidosis with or without known extra-cardiac sarcoid
Exclusion Criteria
* Severe obesity (limited by the scanner)
* Other known significant cardiac disease, including previous myocarditis
* Known tumour disease, especially (neuro)endocrine tumours
* Terminal disease(s), advanced psychiatric disease and/or significant dementia
* Recent or current immunosuppressive treatment
* Recent or current somatostatin analogue (octreotide) therapy
* Known relative/absolute contraindications for contrast-enhanced MRI and/or PET/CT imaging
* Known contraindications for endomyocardial biopsy
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vastra Gotaland Region
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian L Polte, MD, PhD, MSc
Role: PRINCIPAL_INVESTIGATOR
Sahlgrenska University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sahlgrenska University Hospital
Gothenburg, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-001300-38
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.